id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-D-0140-0007,FDA,FDA-2005-D-0140,"Guidance for Industry: Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV), etc.",Notice,NAD-Notice of Availability of Data,2010-04-30T04:00:00Z,2010,4,2010-04-30T04:00:00Z,,2024-11-07T22:14:16Z,2010-10048,1,0,0900006480ae4312
FDA-2005-D-0140-0009,FDA,FDA-2005-D-0140,"Reference 9 - Federal Register, August 24, 2007 (72 FR 48765), Current Good Manufacturing Practice for Blood and Blood Components; Notification of Consignees and Transfussion Recipients Receiving Blood and Blood Components at Increased Risk of Transmitting Hepatitis C Virus Infection (""Lookback""); Final Rule",Supporting & Related Material,BKG-Background Material,2010-04-30T04:00:00Z,2010,4,,,2010-04-30T15:18:15Z,,0,0,0900006480ae387b
FDA-2005-D-0140-0008,FDA,FDA-2005-D-0140,"Guidance for Industry: Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV), etc.",Other,GDL-Guidance (Supporting and Related Materials),2010-04-30T04:00:00Z,2010,4,2010-04-30T04:00:00Z,,2024-11-12T04:52:51Z,,1,0,0900006480ae3879